title: Targeted therapy for localized non-small-cell lung cancer: a review.
abstract: Targeted therapies have markedly improved the management of patients with advanced non-small-cell lung cancer (NSCLC), but their efficacy in localized NSCLC is less well established. The aim of this review is to analyze trials of targeted therapies in localized NSCLC. In patients with wild-type EGFR, tyrosine kinase inhibitors have shown no efficacy in Phase III trials. Few data are available for EGFR-mutated localized NSCLC, as routine biological profiling is not recommended. Available studies are small, often retrospectives, and/or conducted in a single-center making it difficult to draw firm conclusions. Ongoing prospective Phase III trials are comparing adjuvant tyrosine kinase inhibitor administration versus adjuvant chemotherapy. By analogy with the indication of bevacizumab in advanced NSCLC, use of antiangiogenic agents in the perioperative setting is currently restricted to nonsquamous NSCLC. Several trials of adjuvant or neoadjuvant bevacizumab are planned or ongoing, but for the moment there is no evidence of efficacy. Data on perioperative use of biomarkers in early-stage NSCLC come mainly from small, retrospective, uncontrolled studies. Assessment of customized adjuvant or neoadjuvant therapy in localized NSCLC (with or without oncogenic driver mutations) is a major challenge.
authors.affiliation: Chest Department, HIA Clermont Tonnerre, Brest.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Paleiron
authors.affiliation: Chest Department, HIA Percy, Clamart.
authors.forename: Olivier
authors.initials: O
authors.lastname: Bylicki
authors.affiliation: Chest Department, HIA Clermont Tonnerre, Brest.
authors.forename: Michel
authors.initials: M
authors.lastname: André
authors.affiliation: Chest Department, HIA Clermont Tonnerre, Brest.
authors.forename: Emilie
authors.initials: E
authors.lastname: Rivière
authors.affiliation: Chest Department, HIA Clermont Tonnerre, Brest.
authors.forename: Frederic
authors.initials: F
authors.lastname: Grassin
authors.affiliation: Chest Department, CHU de Brest, Brest.
authors.forename: Gilles
authors.initials: G
authors.lastname: Robinet
authors.affiliation: GRC OncoEst, Université Paris XII, Paris, France.
authors.forename: Christos
authors.initials: C
authors.lastname: Chouaïd
keywords: adjuvant; neo-adjuvant; non-small-cell lung cancer; surgery; targeted therapy